Literature DB >> 12759344

Physical and functional interactions between PML and MDM2.

Xiaolong Wei1, Zhong Kang Yu, Arivudainambi Ramalingam, Steven R Grossman, Jiang H Yu, Donald B Bloch, Carl G Maki.   

Abstract

The tumor suppressor protein PML and oncoprotein MDM2 have opposing effects on p53. PML stimulates p53 activity by recruiting it to nuclear foci termed PML nuclear bodies. In contrast, MDM2 inhibits p53 by promoting its degradation. To date, neither a physical nor functional relationship between PML and MDM2 has been described. In this study, we report an in vivo and in vitro interaction between PML and MDM2 which is independent of p53. Two separate regions of PML are recognized which can interact with MDM2. The C-terminal half of PML, encoded by residues 300-633, can interact with the central region of MDM2 which includes the MDM2 acidic domain. In addition, PML amino acids 1-200, which encode the RING-finger and most of the B box zinc binding motifs, can interact with the C-terminal, RING-finger containing region of MDM2. Interestingly, PML mutants in which sumoylation at lysine 160 was inhibited displayed an increased association with MDM2, suggesting that sumoylation at this site may be a determinant of PML-MDM2 binding. Coexpression with MDM2 caused a redistribution of PML from the nucleus to the cytoplasm, and this required the PML N terminus and the MDM2 RING-finger domain. These results suggest that interaction between the PML N terminus and MDM2 C terminus can promote PML nuclear exclusion. Wild-type MDM2 inhibited the ability of PML to stimulate the transcriptional activity of a GAL4-CBP fusion protein. This inhibition required the central, acidic region of MDM2, but did not require the MDM2 C terminus. Taken together, these studies demonstrate that MDM2 and PML can interact through at least two separate protein regions, and that these interactions can have specific effects on the activity and/or localization of PML.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12759344     DOI: 10.1074/jbc.M212215200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

1.  Impairment of p53 acetylation, stability and function by an oncogenic transcription factor.

Authors:  Alessandra Insinga; Silvia Monestiroli; Simona Ronzoni; Roberta Carbone; Mark Pearson; Giancarlo Pruneri; Giuseppe Viale; Ettore Appella; PierGiuseppe Pelicci; Saverio Minucci
Journal:  EMBO J       Date:  2004-02-19       Impact factor: 11.598

2.  The Prp19 U-box crystal structure suggests a common dimeric architecture for a class of oligomeric E3 ubiquitin ligases.

Authors:  Craig W Vander Kooi; Melanie D Ohi; Joshua A Rosenberg; Michael L Oldham; Marcia E Newcomer; Kathleen L Gould; Walter J Chazin
Journal:  Biochemistry       Date:  2006-01-10       Impact factor: 3.162

3.  SUMO E3 ligase activity of TRIM proteins.

Authors:  Y Chu; X Yang
Journal:  Oncogene       Date:  2010-10-25       Impact factor: 9.867

4.  Regulation of E2Fs and senescence by PML nuclear bodies.

Authors:  Mathieu Vernier; Véronique Bourdeau; Marie-France Gaumont-Leclerc; Olga Moiseeva; Virginie Bégin; Fred Saad; Anne-Marie Mes-Masson; Gerardo Ferbeyre
Journal:  Genes Dev       Date:  2011-01-01       Impact factor: 11.361

Review 5.  TRIMming p53's anticancer activity.

Authors:  S Elabd; G Meroni; C Blattner
Journal:  Oncogene       Date:  2016-02-22       Impact factor: 9.867

6.  Evidence that the human cytomegalovirus IE2-86 protein binds mdm2 and facilitates mdm2 degradation.

Authors:  Zhigang Zhang; David L Evers; Joseph F McCarville; Jean-Christophe Dantonel; Shu-Mei Huong; Eng-Shang Huang
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

7.  PML IV/ARF interaction enhances p53 SUMO-1 conjugation, activation, and senescence.

Authors:  Lisa Ivanschitz; Yuki Takahashi; Florence Jollivet; Olivier Ayrault; Morgane Le Bras; Hugues de Thé
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-02       Impact factor: 11.205

8.  Activation of endogenous p53 by combined p19Arf gene transfer and nutlin-3 drug treatment modalities in the murine cell lines B16 and C6.

Authors:  Christian A Merkel; Rafael B da Silva Soares; Anna Carolina V de Carvalho; Daniela B Zanatta; Marcio C Bajgelman; Paula Fratini; Eugenia Costanzi-Strauss; Bryan E Strauss
Journal:  BMC Cancer       Date:  2010-06-22       Impact factor: 4.430

9.  Splicing up mdm2 for cancer proteome diversity.

Authors:  Danielle R Okoro; Melissa Rosso; Jill Bargonetti
Journal:  Genes Cancer       Date:  2012-03

10.  The Many Faces of MDM2 Binding Partners.

Authors:  Maurisa F Riley; Guillermina Lozano
Journal:  Genes Cancer       Date:  2012-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.